Schrodinger(US:SDGR)2026-02-25 21:11Financial Performance - Total revenue for the year ended December 31, 2025, was $255.9 million, with a net loss of $103.3 million[36]. - The software business generated $199.5 million in revenue in 2025, reflecting an 11% increase compared to 2024, while ACV rose to $198.5 million, a 4% increase[40]. - In 2025, the top 20 pharmaceutical companies licensed the company's software solutions, contributing $73.7 million, or 37%, to software revenue and $80.8 million, or 41%, to annual contract value (ACV) for that year[28]. - The ACV for the top 20 pharma cohort increased to $80.8 million in 2025 from $70.0 million in 2024, indicating a growth of approximately 11.4%[57]. - The average ACV per commercial customer with an ACV over $1.0 million grew to $3.9 million in 2025 from $3.3 million in 2024, reflecting a growth of approximately 18.2%[57]. - The gross dollar retention rate for commercial customers was 96% for 2025, demonstrating high customer retention[58]. Drug Discovery and Development - The company achieved drug discovery revenue of $56.4 million in 2025, with a notable equity gain of $47.6 million from the acquisition of Morphic Holding, Inc.[40]. - The company aims to leverage synergies between its software and drug discovery businesses to enhance customer adoption and validate its platform[40]. - The computational platform can evaluate billions of molecules per day, significantly increasing the probability of discovering novel molecules compared to traditional methods that evaluate approximately 1,000 molecules per year[51]. - The company has entered into collaborations with leading biopharmaceutical companies, focusing on various therapeutic areas, including oncology and autoimmune diseases, which have the potential to generate significant income through milestone payments and royalties[74]. - The company is advancing several other proprietary programs in oncology, immunology, and neurology, focusing on modality switch strategies[120]. Clinical Trials and Regulatory Approvals - The company initiated Phase 1 clinical trials for SGR-1505 and SGR-3515, with initial data from SGR-3515 expected in Q2 2026[33]. - SGR-1505 has received orphan drug designation from the FDA for the treatment of mantle cell lymphoma and fast track designation for Waldenström macroglobulinemia[97]. - The FDA cleared the IND for SGR-3515 in April 2024, with initial data from the Phase 1 trial expected in Q2 2026[119]. - The company must submit a protocol for each clinical trial as part of the IND, which includes detailed objectives and safety monitoring parameters[227]. - The FDA requires a 30-day waiting period after filing an IND before clinical trials can begin, allowing for review of safety and risk[218]. Collaborations and Partnerships - The company has entered into a collaboration with Novartis, with potential milestone payments of up to $2.272 billion and tiered royalties on net sales[31]. - The collaboration agreement with Novartis includes a $150.0 million upfront payment and potential milestone payments of up to $2.272 billion, with no revenue recognized as of December 31, 2025[87]. - As of December 31, 2025, the company is eligible to receive up to $482.0 million in total milestone payments from BMS for a neurology target, with $32.0 million already recognized in revenue[84]. - The collaboration with Lilly includes potential milestone payments of up to $420.0 million, with low single- to low double-digit royalties on net sales of products[85]. Intellectual Property and Patents - The company has approximately 40 patents and patent applications related to its software business, with expected expiration between 2026 and 2038[201]. - The company has approximately 68 copyright registrations covering its proprietary software code as of January 20, 2026[207]. - The company has a strategy to file patent applications for key software and programs to secure its intellectual property positions[201]. - The company retains the right to provide support to third parties using licensed software even after termination of the Columbia Agreements[186][191]. Competitive Landscape - The competitive landscape includes major biopharmaceutical companies and emerging startups, with a focus on oncology and novel therapies[151]. - The company faces intense competition in drug discovery, particularly in oncology, with multiple competitors developing similar product candidates[153]. - The company is advancing SGR-3515, a Wee1/Myt1 inhibitor for solid tumors, amidst competition from several other companies in clinical development[155]. Future Plans and Initiatives - The company plans to launch a predictive toxicology solution commercially in 2026, supported by $19.5 million in grants from the Bill & Melinda Gates Foundation[38]. - The predictive toxicology initiative, launched in 2024, aims to improve drug development candidates' properties and is expected to be commercially available in 2026[62]. - The company plans to enter into agreements with biopharmaceutical companies to advance its proprietary drug discovery programs towards commercialization[210]. - The company is actively pursuing strategic alliances to advance its drug discovery programs and improve its computational platform[126].